Karyotypic analysis in primary myelodysplastic syndromes

P. Noël, Ayalew Tefferi, R. V. Pierre, Robert Brian Jenkins, G. W. Dewald

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalBlood Reviews
Volume7
Issue number1
DOIs
StatePublished - 1993

Fingerprint

Myelodysplastic Syndromes
Cytogenetics
Leukemia, Myelomonocytic, Chronic
Refractory Anemia
DNA Probes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence In Situ Hybridization
Chromosomes
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Karyotypic analysis in primary myelodysplastic syndromes. / Noël, P.; Tefferi, Ayalew; Pierre, R. V.; Jenkins, Robert Brian; Dewald, G. W.

In: Blood Reviews, Vol. 7, No. 1, 1993, p. 10-18.

Research output: Contribution to journalArticle

Noël, P. ; Tefferi, Ayalew ; Pierre, R. V. ; Jenkins, Robert Brian ; Dewald, G. W. / Karyotypic analysis in primary myelodysplastic syndromes. In: Blood Reviews. 1993 ; Vol. 7, No. 1. pp. 10-18.
@article{5ae40b32a9bb4a12a3dda8c2e6f5a641,
title = "Karyotypic analysis in primary myelodysplastic syndromes",
abstract = "Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.",
author = "P. No{\"e}l and Ayalew Tefferi and Pierre, {R. V.} and Jenkins, {Robert Brian} and Dewald, {G. W.}",
year = "1993",
doi = "10.1016/0268-960X(93)90019-Z",
language = "English (US)",
volume = "7",
pages = "10--18",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Karyotypic analysis in primary myelodysplastic syndromes

AU - Noël, P.

AU - Tefferi, Ayalew

AU - Pierre, R. V.

AU - Jenkins, Robert Brian

AU - Dewald, G. W.

PY - 1993

Y1 - 1993

N2 - Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.

AB - Cytogenetics has provided new insights into the biology and pathogenesis of myelodysplastic syndromes. In patients with refractory anemia, it has provided proof of clonality and has helped differentiate chronic myelomonocytic leukemia from chronic myeloid leukemia. As a prognostic tool, cytogenetics has been predictive of duration of survival and leukemic transformation. However, its role as an independent prognostic factor compared with recent prognostic scoring systems remains to be determined. New techniques such as fluorescent in situ hybridization using chromosome-specific DNA probes may expand the usefulness of cytogenetics. The prognostic impact of cytogenetics may not be fully realized until more effective treatments become available.

UR - http://www.scopus.com/inward/record.url?scp=0027511657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027511657&partnerID=8YFLogxK

U2 - 10.1016/0268-960X(93)90019-Z

DO - 10.1016/0268-960X(93)90019-Z

M3 - Article

C2 - 8467227

AN - SCOPUS:0027511657

VL - 7

SP - 10

EP - 18

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 1

ER -